Kira Pharmacenticals (US), LLC.

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis	Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder	Not yet recruiting	Phase 2	2024-10-28	NCT05517980
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus	Cytopenia, Hemic and Lymphatic Diseases, Skin and Connective Tissue Diseases, autoimmune disease, blood platelet disease, connective tissue disorder, hematologic disorder, immune system disorder, systemic lupus erythematosus, thrombocytopenia, thrombotic microangiopathy	Not yet recruiting	Phase 2	2024-10-28	NCT05504187
To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of KP104	Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria	Active, not recruiting	Phase 2	2024-10-28	NCT05476887

Clinical trials